Abstract
Clonality assessment via analysis of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements has become an important and valuable adjunct in the diagnostic process of suspect lymphoproliferations. One of the major issues in correct interpretation of clonality testing results appears to be the occurrence of multiple clonal PCR products. The presence of two different PCR products could reflect biclonality but can often more easily be attributed to the occurrence of biallelic rearrangements in a single clone. Furthermore, due to the specific configuration of the IGK and TCRB loci, multiple rearrangements can occur on one allele, resulting in the possibility that up to four PCR products could be compatible with a single clone. Finally, >2 clonal Ig/TCR products (>4 for IGK and TCRB) could reflect biclonality, oligoclonality, or even pseudoclonality. It is not always easy to distinguish between those options, but the use of duplicates will be helpful to determine reproducibility and relevance of the detected clonal PCR products. In conclusion, straightforward interpretation of clonality testing results can be hampered by the occurrence of multiple clonal products. Only careful consideration of immunobiological and technical explanations will prevent incorrect interpretation in such cases.
Similar content being viewed by others
Introduction
Clonality assessment via analysis of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements has become an important and valuable adjunct in the diagnostic process of suspect lymphoproliferations. This holds for histopathologically suspect lymphoid lesions in tissues (lymph nodes, spleen, skin, and gastrointestinal tract) but is similarly true in case of a lymphocytosis or suspect lymphocyte population in bone marrow, peripheral blood, or other body fluids (such as spinal fluid). Initially, such clonality testings could only be done by means of Southern blot analysis [10, 11]. Meanwhile, multiple protocols and primer sets for PCR-based clonality assessment have been developed, initially mainly focusing on two targets: IGH (Ig heavy chain locus) for B cell clonality and TCRG (TCR gamma locus) for T cell clonality. These two targets were mainly chosen because of their broad applicability and because of the limited number of primers required. At the end of the 90s of the previous century, a European BIOMED-2 consortium started to redesign primers and optimize PCR protocols for Ig/TCR clonality testing [12]. This has resulted in standardized multiplex PCR protocols for IGH and TCRG analysis, which showed very good performance when evaluated in large series of WHO-defined lymphoma and leukemia entities [1, 3, 6]. Importantly, the BIOMED-2 consortium (now called EuroClonality) has also developed multiplex PCR protocols for alternative targets for B cell (IGK and IGL, Ig kappa and lambda light chain locus, respectively) and T cell (TCRB and TCRD, TCR beta and delta, respectively) clonality testing. Especially, the IGK and TCRB gene rearrangement assays have proven to be highly informative. Hence, these targets could serve as alternatives for IGH and TCRG, respectively, but also have important complementary value and unprecedented performance when used in combination with IGH and TCRG [1, 3].
Along with the technical standardization of the multiplex PCR protocols and their commercial availability in kit format, these tests have now found their way to routine clonality testing laboratories worldwide. Correct interpretation of the results of these multiplex PCR reactions is, therefore, now the challenge. Via educational workshops, publications, and a website-based support system, the EuroClonality group is actively contributing to optimal use and interpretation of these assays. One of the major issues in correct interpretation of clonality testing results appears to be the occurrence of multiple clonal PCR products. This is especially true for the IGK and TCRB targets due to the intrinsic complexity of the configuration of these two loci. Here, we address the issue of multiple clonal products, evaluate situations in which multiple rearrangements are generated in the IGK and TCRB loci, and discuss the interpretation of multiple products in the context of clonality assessment diagnostics.
Multiple rearrangements can result in multiple clonal products
Both B and T lymphocytes undergo several stages of differentiation. For B lymphocytes, the initial differentiation process takes place in the bone marrow, whereas early T lymphocyte differentiation is in the thymus. A common feature of both differentiation pathways is the fact that the precursor B cells and precursor T cells (also called thymocytes) undergo hierarchical gene rearrangements in their Ig and TCR loci, respectively [2, 13]. B cell precursors start rearranging the IGH locus with an initial D–J gene rearrangement, followed by coupling of a V gene to the D–J recombination; following evaluation of the expressed IgH chain in a preB cell receptor (preBCR) complex, the next step is to create a proper Ig light chain. To this end, the IGK locus first starts to rearrange its V and J genes. If this does not lead to a good Igκ chain, the next step is to rearrange V and J genes in the IGL locus in order to generate a good Igλ chain (Fig. 1a). In an analogous way, thymocytes undergo hierarchical rearrangements in their TCR loci, starting with D–D, D–J, and V–DJ recombinations in the TCRD locus, followed by V–J rearrangements in the TCRG locus. Unless this leads to a proper TCRγδ receptor, the thymocytes will continue to rearrange their TCRB loci (initially D–J, followed by V–DJ rearrangement) and, finally, their TCRA loci (V–J recombinations) (Fig. 1b).
The mere purpose of the whole V(D)J recombination process is thus to create a unique antigen receptor (Ig or TCR molecule) that is positively selected to recognize antigen and negatively selected for showing too high affinity to autoantigens. However, V(D)J recombination is not a directed process. Rather, the coupling of V, (D), and J genes is purely random. Moreover, during the actual coupling process, the involved V, D and J genes are trimmed and nontemplated nucleotides are (randomly) inserted, which further adds to the diversity. Since a proper antigen receptor chain can only be formed if the reading frame of three nucleotides (triplet codons) is preserved, many rearrangements are unproductive (out-of-frame rearrangement or rearrangement with stop codon). This implies that for a given Ig/TCR locus, very frequently two rearrangement attempts have taken place: one on each chromosome (allele). Given that the theoretical chance for a rearrangements to be in the correct reading frame and lacking a stop codon is ~25–30%, this implies that biallelic Ig/TCR gene rearrangements (D–J and/or V–DJ) are thus more rule than exception in B and T lymphocytes.
Since leukemias and lymphomas are the malignant counterparts of normal lymphocytes, it can be appreciated that the tumor clones that derive from a single transformed lymphocyte mostly contain biallelic rearrangements as well. Hence, in PCR-based clonality testing, the combination of two V–(D)J rearrangement products or one incomplete D–J product and a complete V–(D)J product is frequently seen. Even though biallelic rearrangements are thus the most likely underlying biological phenomenon for having two PCR products, the presence of two different clones could also be compatible with multiple products. Indeed, the presence of two parallel clones has been described in leukemia and lymphoma with a frequency of ~5% of cases [9]. That notwithstanding, biallelic rearrangements in lymphoma are often a more logical explanation than biclonality, unless additional evidence is available on the existence of two phenotypically distinct cell populations from either immunohistochemistry or flowcytometry.
Detection of up to two rearrangements per Ig/TCR locus can thus be readily explained by mono- or biallelic rearrangements. However, if three or more PCR products are found, other explanations have to be considered including the existence of two clones (biclonality) or even multiple clones (oligoclonality). In order to distinguish between (biallelic) monoclonality versus biclonality versus multiple clones/oligoclonality, a careful evaluation of the number of distinct PCR products per locus is required (Table 1). However, it may occasionally be difficult to determine which PCR products truly reflect clonal rearrangements. It is, therefore, strongly recommend to always run clonality assays in duplicate. Results from duplicate analyses will disclose the reproducibility of the PCR products in terms of amplicon size and signal intensity, which facilitates proper interpretation of the number of true clonal products (one, two or more). Notably, in case of a limited number of cells (so-called paucicellular samples), often seemingly clear clonal PCR products are detected albeit with nonreproducible amplicon sizes. This is sometimes referred to as pseudoclonality, which is defined as the detection of nonreproducible clonal PCR products due to selective amplification of low amount of template (Table 1). When there is a broad and diverse repertoire, which in fact reflects many different lymphocytes (clones), the term polyclonality is used. Evaluation of two different Ig or TCR targets (IGH plus IGK or TCRG plus TCRB) might sometimes shed light on interpretation of the number of clones present in the lesion. It should be noted, however, that the IGK and TCRB loci are a bit exceptional. Due to their specific configuration, >1 rearrangement can be present on the same chromosome/allele, and hence, three or even four PCR products can easily be compatible with one clone (Table 1). The complexity of the IGK and TCRB loci and the expected type and number of PCR products will be addressed in the next sections in more detail.
Multiple rearrangements in the IGK locus
When during its differentiation a precursor B cell is not successful in creating a productive IGK rearrangement, further recombination between one of the upstream Vκ genes and one of the downstream Jκ genes might occur. In theory, such ongoing recombination can be repeated as long as upstream Vκ genes and downstream Jκ genes are still present on that allele. Alternatively, the second IGK allele will undergo one or more Vκ–Jκ recombinations in an attempt to make a productive IGK rearrangement (in-frame, no stop codon). If all options fail, the precursor B cell will switch to recombination of the IGL locus. Prior to initiation of IGL recombination, however, a completely different type of IGK recombination occurs. This is due to the presence of additional elements in the IGK locus that can be involved in recombination (reviewed in Langerak and Van Dongen [5]) (Fig. 2a). One of these is the so-called Kappa deleting element (Kde), which is located 24 kb downstream of the Cκ region. This Kde can recombine to i) any of the Vκ genes upstream of the unproductive Vκ–Jκ exon (resulting in a Vκ–Kde rearrangement) or ii) the other nonclassical IGK rearrangeable sequence in the intron (intron RSS) between the Jκ genes and the Cκ region (leading to an intron-Kde rearrangement) (Fig. 2b). The effect of both types of rearrangements is a deletion of the Cκ region on the involved allele as well as of the iEκ and 3′Eκ enhancer regions that normally control expression of the IGK locus in cis. The net effect of these recombinations is thus a complete functional inactivation of the involved IGK allele. In the case of a Vκ–Kde rearrangement, the preexisting Vκ–Jκ recombination is thereby removed (Fig. 2b). However, in the other scenario in which an intron-Kde rearrangement is employed to inactivate the IGK locus, the prior Vκ–Jκ recombination will be preserved. As a consequence, two different IGK rearrangements now reside on the same allele: a Vκ–Jκ rearrangement plus an intron-Kde rearrangement (Fig. 2b).
Depending on the exact configuration of its two IGK alleles, up to four rearrangements can thus be present in one cell (Table 2). This phenomenon has major implications for interpretation of multiple PCR products in IGK clonality testing. The BIOMED-2 multiplex IGK assay consists of two reaction mixtures, one targeting the classical Vκ–Jκ rearrangements (tube A) and the other targeting the Kde rearrangements (tube B). Both assays are very informative and have proven their clear complementary value in clonality testing [3]. Particularly, the Kde assay has an enormous advantage because it targets rearrangements that are free of somatic hypermutations, thus reducing the rate of false negativity. However, when applying both IGK assays (Vκ–Jκ rearrangements plus Kde rearrangements) cautious interpretation is thus warranted due to the biological complexity of the IGK locus. In fact, per assay, a total of two rearrangements can be detected per clone (similar to other Ig/TCR loci), but for both IGK multiplex assays, together this can mount to four distinct PCR products in a single B cell clone (Fig. 3; Table 2). A practical approach when dealing with complex IGK patterns from multiplex tubes A and B would be to interpret the pattern of a given case along with the configurations as mentioned in Table 2. This will help to evaluate if and how the clonal products could belong to the same clone. As IGH patterns will often be available as well, this will almost always help to confirm or exclude the monoclonal character of the suspect B cell population. Only in ambiguous cases might sequencing of the products be necessary to solve interpretation.
For reasons of completeness, it is good to mention that yet other rearrangements involving the intron RSS element can occur in the human IGK locus [4]. However, as these so-called J–intron rearrangements are quite rare and not detectable with the IGK multiplex clonality assays, they are beyond the scope of this paper and thus not further discussed here.
One other complicating aspect of the human IGK locus is worth mentioning here as it may influence interpretation of multiple PCR products. Contrary to other Ig/TCR loci, the Vκ genes are organized in two different clusters: a proximal cluster just upstream of the Jκ genes and a distal cluster further upstream (Fig. 2a). This 3′ distal cluster has most probably arisen by duplication during evolution. The involved Vκ genes in this distal cluster show an inverted orientation, implying that an inversional rearrangement is required to form a V–J recombination. As during an inversional rearrangement no DNA is removed from the genome, this Vκ–Jκ recombination will be preserved upon a second inversional Vκ–Jκ rearrangement (Fig. 2c). Consequently, theoretically, two or more Vκ–Jκ rearrangements would be detectable on the same allele if ongoing recombinations occur multiple times in an attempt to obtain a productive IGK allele. This inversional rearrangement process would imply that even more Vκ–Jκ PCR products belonging to one clone might be detectable in a given case. It is quite hard to address this phenomenon experimentally or to estimate the extent of its occurrence, but it is something that should be considered when interpreting IGK clonality testing data.
Finally, some of the Vκ primers in the multiplex assay are known to show some level of cross-reactivity to particular genes of other Vκ families. As the bindings sites for the different Vκ family primers are not all clustered in the same area, this might sometimes give an additional (weak) PCR product next to the correct Vκ–Jκ PCR product. Collectively, this means that there is no direct relationship between the number of clonal IGK PCR products and the number of B cell clones, and that caution is needed in interpreting IGK clonality testing results.
Multiple rearrangements in the TCRB locus
Notably, all Ig and TCR loci roughly have a similar genomic configuration, with a cluster of V genes, a cluster of D genes (at least for some loci), and a cluster of J genes. However, the configuration of the TCRB locus is slightly different in the sense that the two Dβ genes are not clustered but rather dispersed. Moreover, each of these Dβ genes comes with its own set of Jβ genes (Fig. 4). This configuration of two Dβ–Jβ clusters has probably arisen through duplication during evolution and has clear implications for rearrangement detection.
If during differentiation a thymocyte has not productively rearranged its TCRD and TCRG genes to form a functional TCRγδ receptor, recombination will start in the TCRB locus (Fig. 1b). Normally, as a first step in TCRB recombination one of the two Dβ genes will be coupled to one of the Jβ genes. As a direct consequence of the specific TCRB configuration with two separated Dβ–Jβ regions (β1 and β2 areas), two different Dβ–Jβ rearrangements might be formed on the same allele. If during further differentiation the thymocyte continues to rearrange its TCRB locus, one of these two Dβ–Jβ recombinations will be completed to a Vβ–Dβ–Jβ rearrangement. In case this Vβ–Dβ–Jβ rearrangement involves the prior Dβ2–Jβ2 recombination, the entire intergenic region including the already formed Dβ1–Jβ1 recombination will be removed on the circular excision product. Conversely, if the Vβ–Dβ–Jβ rearrangement involves the prior Dβ1–Jβ1 recombination, the more downstream located Dβ2–Jβ2 recombination will now be preserved on the same allele (Fig. 4). Hence, based on the exact type of rearrangements that occur on the two TCRB alleles, multiple PCR products might be amplified from one clone. When evaluating only the two complementary Vβ–Jβ multiplex PCR assays (BIOMED-2 tubes A and B), the number of PCR products (of correct size) is limited to two. However, if also Dβ–Jβ rearrangements (BIOMED-2 TCRB tube C) are evaluated, the number of distinct PCR products compatible with one clone could mount to four (Table 3).
Apart from the multiple rearrangements on one allele, another phenomenon might complicate TCRB analysis with respect to multiple PCR products. Both Vβ–Jβ and Dβ–Jβ rearrangements could give rise to the occurrence of additional PCR products of extended size. This is to be explained by the relatively small intergenic Jβ gene distances of sometimes just 100–150 bp. As both TCRB multiplex PCR mixtures consist of Jβ gene-specific primers, occasionally this would allow additional amplification of a particular Vβ–Jβ/Dβ–Jβ rearrangement from the Jβ gene immediately downstream of the Jβ gene that is involved in the actual rearrangement [7, 8]. When the primer for the downstream Jβ gene is present in the same mixture, this will give rise to double products (of distinct size) in the same PCR reaction (Fig. 5). Even more subtle is the situation that the Vβ–Jβ rearrangement gives rise to an amplicon of the correct size in the one reaction (amplified with the true Jβ primer) and to an extended amplicon in the other PCR reaction (amplified with a primer for the downstream Jβ gene). The phenomenon of extended PCR products (including TCRB) is discussed in much more detail in the article by Rothberg et al. (this issue of the journal).
Similar to what has been discussed for complex IGK patterns, the presence of multiple TCRB products should also be interpreted in comparison to the possible TCRB configurations (Table 3), while taking into account the phenomenon of extended TCRB products as well.
Concluding remarks on interpretation of multiple clonal products
Knowledge on the immunobiological phenomena leading to multiple clonal Ig or TCR products is a key issue for correct interpretation of clonality testing results. Although an obvious relation exists between the number of clonal products for a given Ig/TCR locus and the number of B/T cell clones (spectrum of monoclonality–biclonality–oligoclonality–polyclonality), the situation is not always that straightforward. First, the presence of two different PCR products could reflect biclonality but can often more easily be attributed to the occurrence of biallelic rearrangements in a single clone. Second, due to the specific configuration of the IGK and TCRB loci, multiple rearrangements can occur on one allele resulting in the possibility that up to four PCR products could be compatible with a single clone. Finally, when >2 clonal Ig/TCR products (>4 for IGK and TCRB) are detectable, this could reflect biclonality, oligoclonality, or even pseudoclonality. It is not always easy to distinguish between those options but the use of duplicates will be helpful to determine reproducibility and relevance of the detected clonal PCR products. In conclusion, straightforward interpretation of clonality testing results can be hampered by the occurrence of multiple clonal products. Only careful consideration of immunobiological and technical explanations will prevent incorrect interpretation in such cases.
References
Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJTA, Sambade S, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau MH, Kneba M, Van Dongen JJM, Macintyre EA, Molina TJ (2007) Powerful strategy for PCR-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:215–221
Dik WA, Pike-Overzet K, Weerkamp F, De Ridder D, De Haas EF, Baert MRM, Van der Spek P, Koster EEL, Reinders MJT, Van Dongen JJM, Langerak AW, Staal FJT (2005) New insights on human T-cell development by quantitative T-cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 201:1715–1723
Evans PA, Pott Ch, Groenen PJ, Salles G, Davi F, Berger F, Garcia JF, van Krieken JH, Pals S, Kluin P, Schuuring E, Spaargaren M, Boone E, González D, Martinez B, Villuendas R, Gameiro P, Diss TC, Mills K, Morgan GJ, Carter GI, Milner BJ, Pearson D, Hummel M, Jung W, Ott M, Canioni D, Beldjord K, Bastard C, Delfau-Larue MH, van Dongen JJM, Molina TJ, Cabeçadas J (2007) Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:207–214
Langerak AW, Nadel B, De Torbal A, Wolvers-Tettero ILM, Van Gastel-Mol EJ, Verhaaf B, Jaeger U, Van Dongen JJM (2004) Unraveling the consecutive recombination events in the human immunoglobulin kappa (IGK) locus. J Immunol 173:3878–3888
Langerak AW, Van Dongen JJM (2006) Recombination in the human IGK locus. Crit Rev Immunol 26:23–42
Langerak AW, Molina TJ, Lavender FL, Pearson D, Flohr T, Sambade C, Schuuring E, Al Saati T, van Dongen JJ, van Krieken JH (2007) Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 21:222–229
Langerak AW, Groenen PJTA, Van Krieken JHJM, Van Dongen JJM (2007) Ig/TCR clonality diagnostics. Exp Opin Med Diagn 1:451–461
Langerak AW (2008) Undersized, oversized? It is not one-size-fits-all in lymphoid clonality detection. Leukemia Res 32:203–204
Sanchez ML, Almeida J, Gonzalez D, Gonzalez M, Garcia-Marcos MA, Balanzategui A, Lopez-Berges MC, Nomdedeu J, Vallespi T, Barbon M, Martin A, de la Fuente P, Martin-Nuñez G, Fernandez-Calvo J, Hernandez JM, San Miguel JF, Orfao A (2003) Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 102:2994–3002
Van Dongen JJM (1987) Analysis of immunoglobulin genes and T cell receptor genes as a diagnostic tool for the detection of lymphoid malignancies. Neth J Med 31:201–209
Van Dongen JJ, Hooijkaas H, Michiels JJ, Grosveld G, de Klein A, van der Kwast TH, Prins ME, Abels J, Hagemeijer A (1984) Richter’s syndrome with different immunoglobulin light chains and different heavy chain gene rearrangements. Blood 64:571–575
Van Dongen JJM, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender L, Delabesse E, Davi F, Schuuring E, Garcia Sanz R, Van Krieken JHJM, Droese J, Gonzalez D, Bastard C, Spaargaren M, San Miguel JF, Parreira A, Smith JF, Morgan G, Kneba M, Macintyre EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene rearrangements in suspect lymphoproliferations. Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317
Van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Révész T, Staal FJ, van Dongen JJ (2005) Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol 175:5912–5922
Acknowledgments
We thank our colleagues from the BIOMED-2/EuroClonality network for fruitful discussions and the members of the clonality lab, Dept. of Immunology, Erasmus MC (Ingrid Wolvers, Ellen van Gastel, Brenda Verhaaf, Dennis Tielemans, Joyce Vermeulen, and Ashley van der Spek), for their continuous support and valuable contributions to this study. We acknowledge Sandra de Bruin-Versteeg for help in preparing figures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Langerak, A.W., van Dongen, J.J.M. Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. J Hematopathol 5, 35–43 (2012). https://doi.org/10.1007/s12308-011-0129-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12308-011-0129-1